Cart
sales@molnova.com
SRX3207
CAS No. 2254693-15-5
SRX3207( —— )
Catalog No. M33816 CAS No. 2254693-15-5
SRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 129 | Get Quote |
|
| 5MG | 206 | Get Quote |
|
| 10MG | 309 | Get Quote |
|
| 25MG | 484 | Get Quote |
|
| 50MG | 638 | Get Quote |
|
| 100MG | 875 | Get Quote |
|
| 500MG | 1755 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSRX3207
-
NoteResearch use only, not for human use.
-
Brief DescriptionSRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression.
-
DescriptionSRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.
-
In VitroSRX3207 (10 μmol/L) is able to block p-AKT at concentration.SRX3207 has sufficient solubility in water (43 μmol/L).
-
In VivoSRX3207 (10 mg/kg, orally) increases antitumor immune response.Animal Model:LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice.Dosage:10 mg/kg.Administration:Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21.Result:Blocked phosphorylation of Syk at 348 site and Y525/526 site.Blocked immunosuppressive MΦ polarization.Blocked tumor growth and increased survival effectively.
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K | Syk
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2254693-15-5
-
Formula Weight555.65
-
Molecular FormulaC29H29N7O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 5 mg/mL (9.00 mM; Ultrasonic )
-
SMILESCc1nn(cc1CN1CCC1)-c1ccnc(Nc2ccc(cc2)-c2csc3c2oc(cc3=O)N2CCOCC2)n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.
molnova catalog
related products
-
GDC-0941
A potent, selective, orally bioavailable inhibitor of class I PI3Ks with IC50 of 3/33/3/75 nM for p110α/β/γ/δ, respectively.
-
BAY 80-6946
BAY 80-6946 (Copanlisib) is a potent and highly selective reversible PI3K inhibitor for PI3Kα/β with IC50 of 0.469 nM/3.72 nM. Phase 2.
-
CYH33 methanesulfona...
CYH33 (CYH-33) is a novel potent, PI3Kα-selective inhibitor with IC50 of 5.9 nM/598 nM/ 78.7 nM/225 nM aginst class I PI3K isoform α/β/δ/γ, respectively.
